Company ProfilePremium

Valeant Pharmaceuticals International, Inc.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Valeant Pharmaceuticals International, Inc. - Healthcare showcase

Year Founded & Workforce

1960

Industry

Healthcare

Services

IBS-DAesthetics
V

Valeant Pharmaceuticals International, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Valeant Pharmaceuticals International, Inc. Overview

Incorporated in 1960 and headquarters in Laval, Canada. Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical and medicinal device organization that creates, Develops and showcases an expansive scope of prescription and non-prescription pharmaceutical products that have an important effect in patients' lives all through more than 100 nations. Valeant's essential focus is in the regions of dermatology and eye health.

Valeant Pharmaceuticals International, Inc. has a set up a portfolio of durable products and their primary strategy is to focus the business on core geographies and therapeutic areas that offer high-development opportunities. Valeant’s premeditated markets are principally in the United States, Canada, Europe, the Middle East, Latin America, Asia Pacific and Africa. The company has employee strength of 10,000+ employees.

Company Snapshot

$10,447M

Revenue

1960

Founded

SWOT Analysis

Strengths

  • Innovative product portfolio
  • Products available globally
  • Strong presence in the US and Canada
  • Strong portfolio

Weaknesses

  • Constant decrease in profitability
  • Low presence in emerging markets

Opportunities

  • Strategic investments in mergers and acquisitions to increase the company’s product portfolio

Threats

  • Changing competitive landscape
  • High competition
  • Threat from generic drug manufacturers

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
–FDA ApprovalSalix Pharmaceuticals, Inc. announced the FDA approval of Xifaxan 550 mg for the treatment of IBS-D.
–AcquisitionValeant acquired Salix Pharmaceuticals, the largest gastroenterology-focused pharmaceutical company in the world.

Product Offering

  • Valeant Pharmaceuticals International, Inc.
    • IBS-D
    • Aesthetics

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales fell from USD 10,447 Mn in 2015 to USD 8,724 Mn in 2017.
Valeant Pharmaceuticals International, Inc. — By Business Segment
Series (USD Mn)201520162017
Sales10,4479,6748,724
R&D Expenses335426358

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.